Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
1. Pfizer will acquire Metsera for $7.3 billion, boosting obesity drug market presence. 2. Metsera's stock surged 60% in premarket trading following acquisition announcement. 3. Analysts project Metsera's drugs could exceed $5 billion in peak annual sales. 4. Pfizer's struggles with its own obesity candidates pressured it to make this acquisition. 5. The obesity drug market could be worth $100 billion by the 2030s.